

IN THE UNITED STATES

AND TRADEMARK OFFICE

Applicant(s): Elazar Rabbani et

Serial No. 08/978,635

Group Art Unit: 1635

Filed: November 25, 1997

Examiner: Mary M. Schmidt

Title PROCESS FOR SELECTIVE EXPRESSION OF NUCLEIC ACID PRODUCTS

FILED BY FIRST CLASS MAILHonorable Commissioner of
Patents and Trademarks
Washington, D. C. 20231

Sir:

Transmitted herewith is an Amendment Under 37 C.F.R. § 1.115 (In Response To The February 16, 1999 Office Action) issued in the above-identified patent application.

The fee* has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total	7	Minus	30	0 =	X\$9.00	\$ 0
Indep	1	Minus	3	0 =	X\$39.00	\$ 0
()	First Presentation of Multiple Dependent Claims				\$130.00	\$
	TOTAL ADDITIONAL FEE					\$ 0

*Small entity status was previously established in this application and is still applicable.

() Charge Deposit Account No. 05-1135 in the amount of \$ _____

() A check in the amount of \$ _____ is attached.

(X) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 05-1135 any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims and any patent application processing fees under 37 C.F.R. §1.17.


Copies are being provided in triplicate.

Also enclosed: Request For An Extension Of Time (Three Months); Second Amendment In Connection With Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures Under 37 CFR §§1.821-1.825; Communication Directed To Notice To Comply With Sequence Rules; Initial Paper Copy of the Sequence Listing; Computer Readable Form copy of the Sequence Listing; Declaration Under 37 CFR §1.821(g)

August 16, 1999
Date

ENZO THERAPEUTICS, INC.
c/o Enzo Biochem, Inc.
527 Madison Avenue (9th Fl.)
New York, New York 10022
Tel. (212) 583-0100
Attorney's Docket No.: Enz-53(D2)

Respectfully submitted,




Ronald C. Fedus

Registration No. 32,567

Attorney for **First Class Certificate**

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as first class mail in an envelope addressed to:
Commissioner of Patents & Trademarks Washington, D.C. 20231


Ronald C. Fedus
Reg. No. 32,567

AUG 16 99
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elazar Rabbani et al

Serial No. 08/978,635

Filed November 25, 1997

Title: NOVEL PROPERTY EFFECTING
AND/OR PROPERTY EXHIBITING
COMPOSITIONS FOR THERAPEUTIC
AND DIAGNOSTIC USE

Group Art Unit: 1635

Examiner: Mary M. Schmidt

527 Madison Avenue, 9th Floor
New York, New York 10022
August 16, 1999

FILED VIA FIRST CLASS MAIL

Honorable Commissioner
of Patents and Trademarks
Washington, D.C. 20231

Attention: Box Sequence

**SECOND COMMUNICATION DIRECTED TO NOTICE
TO COMPLY WITH SEQUENCE RULES**


Dear Sirs:

Pursuant to the Office Action issued February 16, 1999 in connection with the instant application, this Second Communication follows Applicants' June 8, 1998 Communication directed to the Notice To Comply With Sequence Rules that was attached to the Notice to File Missing Parts of Application – Filing Date Granted mailed January 26, 1998 in connection with the above-identified application.

Applicants hereby submit the following documents or items:

1. a substitute initial paper copy of the substitute Sequence Listing;
2. a Second Amendment directing entry of the substitute Sequence Listing into the specification;
3. a copy of the Raw Sequence Listing Error Report attached to the February 16, 1999 Office Action issued in the instant application; and

ENZ-53(D4)




4. a computer readable form (CFR) copy of the substitute Sequence Listing; and
5. a Declaration Under 37 C.F.R. §1.821(g) attesting that the content of the substitute paper and substitute computer readable copies are the same and include no new matter.

No fee is believed due in connection with this Communication or the documents or items submitted herewith other than the fee payment authorized in the Request For an Extension Of Time (Three Months) Under 37 C.F.R. §1.136(a). If any other fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Communication, the undersigned may be contacted by telephone at (212) 583-0100 during the daytime hours.

Respectfully submitted,



Ronald C. Fedus
Registration No. 32,567
Attorney for Applicants

ENZO THERAPEUTICS, INC.
c/o Enzo Biochem, Inc.
527 Madison Avenue (9th Fl.)
New York, New York 10022
(212) 583-0100